TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Ettl, K. PY - 2016 DA - 2016// TI - Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0721-5 DO - 10.1186/s13058-016-0721-5 ID - Finn2016 ER - TY - JOUR AU - Rugo, H. S. AU - Diéras, V. AU - Gelmon, K. A. PY - 2018 DA - 2018// TI - Impact of palbociclib plus letrozole on patient reported health-related quality of life: results from the PALOMA-2 trial JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy012 DO - 10.1093/annonc/mdy012 ID - Rugo2018 ER - TY - JOUR AU - Cristofanilli, M. AU - TUrner, N. C. AU - Bondarenko, I. PY - 2016 DA - 2016// TI - Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00613-0 DO - 10.1016/S1470-2045(15)00613-0 ID - Cristofanilli2016 ER - TY - JOUR AU - Malorni, L. AU - Curigliano, G. AU - Minisini, A. M. AU - Cinieri, S. AU - Tondini, C. A. AU - D’Hollander, K. AU - Arpino, G. AU - Bernardo, A. AU - Martignetti, A. AU - Criscitiello, C. AU - Puglisi, F. AU - Pestrin, M. AU - Sanna, G. AU - Moretti, E. AU - Risi, E. AU - Biagioni, C. AU - McCartney, A. AU - Boni, L. AU - Buyse, M. AU - Migliaccio, I. AU - Biganzoli, L. AU - Di Leo, A. PY - 2018 DA - 2018// TI - Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial JO - Annals of Oncology VL - 29 UR - https://doi.org/10.1093/annonc/mdy214 DO - 10.1093/annonc/mdy214 ID - Malorni2018 ER - TY - JOUR AU - Finn, R. S. AU - Dering, J. AU - Conklin, D. PY - 2009 DA - 2009// TI - PD0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro JO - Breast Cancer Res VL - 11 UR - https://doi.org/10.1186/bcr2419 DO - 10.1186/bcr2419 ID - Finn2009 ER - TY - BOOK AU - Finn, R. S. AU - Crown, J. P. AU - Ettl, J. PY - 2015 DA - 2015// TI - Treatment patterns of post-disease progression in the PALOMA-1/TRIO-18 trial, SABCS ID - Finn2015 ER - TY - JOUR AU - Turner, N. i. c. h. o. l. a. s. C. AU - Slamon, D. e. n. n. i. s. J. AU - Ro, J. u. n. g. s. i. l. AU - Bondarenko, I. g. o. r. AU - Im, S. e. o. c. k. -. A. h. AU - Masuda, N. o. r. i. k. a. z. u. AU - Colleoni, M. a. r. c. o. AU - DeMichele, A. n. g. e. l. a. AU - Loi, S. h. e. r. e. n. e. AU - Verma, S. u. n. i. l. AU - Iwata, H. i. r. o. j. i. AU - Harbeck, N. a. d. i. a. AU - Loibl, S. i. b. y. l. l. e. AU - André, F. a. b. r. i. c. e. AU - Puyana Theall, K. a. t. h. y. AU - Huang, X. i. n. AU - Giorgetti, C. a. r. l. a. AU - Huang Bartlett, C. y. n. t. h. i. a. AU - Cristofanilli, M. a. s. s. i. m. o. PY - 2018 DA - 2018// TI - Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer JO - New England Journal of Medicine VL - 379 UR - https://doi.org/10.1056/NEJMoa1810527 DO - 10.1056/NEJMoa1810527 ID - Turner2018 ER - TY - JOUR AU - O'Shaughnessy, J. AU - Petrakova, K. AU - Sonke, G. S. PY - 2018 DA - 2018// TI - Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial JO - Breast Cancer Res Treat VL - 168 UR - https://doi.org/10.1007/s10549-017-4518-8 DO - 10.1007/s10549-017-4518-8 ID - O'Shaughnessy2018 ER - TY - JOUR AU - Slamon, D. J. AU - Neven, P. AU - Chia, S. PY - 2018 DA - 2018// TI - Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 JO - J Clin Oncol VL - 3 ID - Slamon2018 ER - TY - JOUR AU - Dickler, M. N. AU - Tolaney, S. M. AU - Rugo, H. S. PY - 2017 DA - 2017// TI - MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0754 DO - 10.1158/1078-0432.CCR-17-0754 ID - Dickler2017 ER - TY - JOUR AU - Sledge, G. W. AU - Toi, M. AU - Neven, P. PY - 2017 DA - 2017// TI - MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.7585 DO - 10.1200/JCO.2017.73.7585 ID - Sledge2017 ER - TY - JOUR AU - Goetz, M. P. AU - Toi, M. AU - Campone, M. PY - 2017 DA - 2017// TI - MONARCH 3: abemaciclib as initial therapy for advanced breast cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.75.6155 DO - 10.1200/JCO.2017.75.6155 ID - Goetz2017 ER - TY - JOUR AU - Chia, S. AU - Gradishar, W. AU - Mauriac, L. PY - 2008 DA - 2008// TI - Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.5822 DO - 10.1200/JCO.2007.13.5822 ID - Chia2008 ER - TY - JOUR AU - Blum, J. L. AU - Jones, S. E. AU - Buzdar, A. U. PY - 1999 DA - 1999// TI - Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.2.485 DO - 10.1200/JCO.1999.17.2.485 ID - Blum1999 ER - TY - JOUR AU - Jeselsohn, R. AU - Buchwalter, G. AU - Angelis, C. PY - 2015 DA - 2015// TI - ESR1 mutations – a mechanism for acquired endocrine resistance in breast cancer JO - Nat Rev Clin Oncol VL - 12 UR - https://doi.org/10.1038/nrclinonc.2015.117 DO - 10.1038/nrclinonc.2015.117 ID - Jeselsohn2015 ER -